Soralimixin
Soralimixin (BRII-693), a Polymyxin derivative, is a next-generation intravenous (IV)-administered synthetic macrocyclic peptide antibiotic. Soralimixin can be used for the study of infections caused by drug-resistant Gram-negative pathogens.
For research use only. We do not sell to patients.
- CAS No.: 1814918-91-6
- Formula: C48H80Cl2N16O13
- Molecular Weight:1160.15
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All Antibiotic Isoforms
More
Biological Activity
Description
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 1814918-91-6
-
Molecular Weight 1160.15
-
Formula C48H80Cl2N16O13
-
Synonyms
BRII-693; QPX9003
-
Sequence
{Dab(2,4-dichlorobenzaldehyde)}-{Thr}-{Dpr}-{Dab}-{Dab}-{d-Leu}-{Abu}-{Dab}-{Dab}-{Thr} (Lactam bridge: Dab4-Thr10)
-
Sequence Shortening
{Dab(2,4-dichlorobenzaldehyde)}-{Thr}-{Dpr}-{Dab}-{Dab}-{d-Leu}-{Abu}-{Dab}-{Dab}-{Thr} (Lactam bridge: Dab4-Thr10)
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
How to Select the Route of Administration for Mammals
Route-of-administration selection in mammals is a pharmacokinetic, pharmacodynamic, formulation, animal-welfare, and translational decision, not a default technical choice. The selected route should match the study goal: intravenous dosing is most useful when complete systemic exposure and rapid onset are required, oral dosing is most translational for orally intended medicines but is affected by absorption and first-pass metabolism, subcutaneous or intramuscular dosing can provide slower systemic exposure, and intraperitoneal dosing can be useful in rodent proof-of-concept studies but may have limited clinical translation. Published route-comparison studies show that the same compound can produce different exposure, onset, bioavailability, tissue distribution, and tolerability depending on route; therefore, route choice should be supported by pilot pharmacokinetic or pharmacodynamic evidence when the literature is insufficient. Unresolved questions include how to standardize route sel
-
Gram Staining of Tissue Sections
Gram staining of tissue sections is a histochemical technique used to differentiate Gram-positive and Gram-negative bacteria within histological specimens based on differences in bacterial cell wall structure and dye retention, adapted from classical bacteriological Gram staining into tissue-compatible “histological Gram stain” variants. In tissue applications, modifications of the Brown-Hopps and Brown-Brenn methods are commonly used to improve differentiation of microorganisms embedded within host connective tissue and to reduce overstaining or loss of Gram-negative signal, which are known limitations of earlier approaches. The principle relies on crystal violet-iodine complex retention in Gram-positive organisms and subsequent decolorization and counterstaining steps that allow contrast visualization of Gram-negative organisms against tissue background.
Purity & Documentation
References
[1]. Watkins M, et al. Phase 1 study of the safety, tolerability, and pharmacokinetics of a synthetic macrocyclic peptide antibiotic (BRII-693) in healthy adult participants. Antimicrob Agents Chemother. 2025 Jan 31;69(1):e0128824. [Content Brief]
[2]. Iovleva A, et al. Treatment Approaches for Carbapenem-Resistant Acinetobacter baumannii Infections. Drugs. 2025 Jan;85(1):21-40. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)